Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor
NCT03921294 · Indiana Hemophilia &Thrombosis Center, Inc. · PHASE4 · terminated · last registry update 2024-04-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Global COVID-19 pandemic prevented further study visits or enrollment.” | – | Registry record, Indiana Hemophilia &Thrombosis Center, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-10Results posted on the registry: BioMarin Pharmaceutical, valoctocogene roxaparvovec (NCT02576795)
- 2025-01-16Results posted on the registry: Swedish Orphan Biovitrum, a drug against F9 (NCT05856266)
- 2025-01-16Also stopped (terminated): Swedish Orphan Biovitrum, a drug against F9 (NCT05856266)
- 2024-12-13Also stopped (withdrawn): Spark Therapeutics, Inc., SPK-8011 (NCT06297486)
- 2024-11-26Results posted on the registry: Washington University School of Medicine, Transdermal patch + Daily Sublingual Tablet (NCT05010707)
- 2024-07-19Results posted on the registry: Sangamo Therapeutics, SB-FIX (NCT02695160)
- 2024-07-19Also stopped (terminated): Sangamo Therapeutics, SB-FIX (NCT02695160)
- 2024-06-14Results posted on the registry: Hoffmann-La Roche, Emicizumab (NCT04431726)
- 2024-05-16Results posted on the registry: Medexus Pharma, Inc., APVO101 (NCT03855280)
- 2024-05-03Phase 3 first posted: CSL Behring, Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) (NCT06399289)
- 2024-04-18Also stopped (terminated): Hospices Civils de Lyon, Blood sample (NCT05127681)
- 2024-04-04Results posted on the registry: BioMarin Pharmaceutical, valoctocogene roxaparvovec (NCT04323098)
- 2024-03-27Results posted on the registry: Pfizer, PF-06838435/ fidanacogene elaparvovec (NCT03861273)
- 2024-03-07Phase 3 first posted: Spark Therapeutics, Inc., SPK-8011 (NCT06297486)
- 2024-03-06Results posted on the registry: Hoffmann-La Roche, Emicizumab (NCT03315455)
- 2024-01-25Phase 3 first posted: BioMarin Pharmaceutical, Valoctocogene roxaparvovec (NCT06224907)
- 2024-01-05Also stopped (withdrawn): Emory University, Nuwiq (low dose protocol) + HEMLIBRA (NCT04030052)
- 2023-12-29Results posted on the registry: Novo Nordisk A/S, nonacog beta pegol (NCT02141074)
- 2023-12-05Phase 3 first posted: Chulalongkorn University, "Emicizumab", "HEMLIBRA®" (NCT06155955)
- 2023-11-28Results posted on the registry: BioMarin Pharmaceutical, valoctocogene roxaparvovec (NCT03370913)
- 2023-08-22Phase 3 first posted: CSL Behring, CSL222 (AAV5-hFIXco-Padua) (NCT06003387)
- 2023-07-20Also stopped (terminated): Spur Therapeutics, FLT180a (NCT03641703)
- 2023-07-11Results posted on the registry: HealthPartners Institute, 4-factor prothrombin complex concentrate (4FPCC) (NCT03064035)
- 2023-05-30Phase 3 first posted: Novo Nordisk A/S, NNC0365-3769 (Mim8) PPX (NCT05878938)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision